Outpatient Profile in Anxiolytic and/or Antidepressant Treatment

  • Laína Oyague López
    Facultad de Medicina. Universidad de Salamanca mateos[at]usal.es
  • Ramona Mateos Campos
    Facultad de Medicina. Universidad de Salamanca.

Abstract

Prescription of anxiolytic, hypnotic benzodiazepines and antidepressant drugs has experienced a remarkable increase during recent years. Due to their central effects, these drugs are currently being widley used in the treatment of pathologies such as insomnia, anxiety or depression. The object of this study is to draw the profile of outpatients undergoing treatment with any of the aforementioned active principles. Thus, a cross-sectional descriptive epidemiological study was carried out. In this context, patients meeting the study’s inclusión criteria were invited to fill in a questionnaire. During the questionnaire design phase, all technical specifications of the active principles being commercialised in Spain wich fall within the anxiolytic, hypnotic benzodizepines or antidepressant groups were consulted. A total of 104 questionnaires were collected and data compiled and analyzed using a database system.It was noted that the consumption of anxiolytic and antidepressant drugs is more frequent among female patients and that it increases with patients age. Retired people are the greatest consumers of anxiolytic drugs and so are active workers for the antidepressant group. In general, they are long-term treatments. Lorazepam is the anxiolytic drug most frequently prescribed, while Escitalopram is the top one within the antidepressant group.
  • Referencias
  • Cómo citar
  • Del mismo autor
  • Métricas
AEMPS: Agencia Española de Medicamentos y Productos Sanitarios [Internet]. Madrid: AEMPS; c2013 [citado el 9 de junio 2018] Centro de Información Online de Medicamentos; Fichas Técnicas. Disponible en: https://cima.aemps.es/cima/publico/home.html

AEMPS: Agencia Española del Medicamento y Productos Sanitarios. Observatorio del Uso de Medicamentos. Utilización de Medicamentos Ansiolíticos e Hipnóticos en España Durante el Periodo 2000-2012. [Internet]. Madrid: AEMPS; 2014 [actualizado 27 enero 2014; citado 10 febrero 2018] Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/ansioliticos_hipnoticos- 2000-2012.pdf

AEMPS: Agencia Española del Medicamento y Productos Sanitarios. Observatorio del Uso de Medicamentos. Utilización de Medicamentos Antidepresivos en España Durante el Periodo 2000-2013. [Internet]. Madrid: AEMPS; 2015 [actualizado 14 enero 2015; citado 10 febrero 2018] Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/observatorio/docs/antidepresivos-2000- 2013.pdf

Álamo González C, Alonso Álvarez ML, Cañellas Dols F, Martín Águeda B, Pérez Díaz H, Romero Santos-Tomás O et al. Pauta de Actuación y Seguimiento: Insomnio. Madrid: Sociedad Española del Sueño; 2016.

Aparicio Basuri, Arbesú Prieto J, Guerrero Iturralde A, Iglesias Rivero R, Martínez Acebal A, Noriega Morán M et al. Guía de Recomendaciones Clínicas: Ansiedad. Asturias: Consejería de Sanidad y Servicios del Principado de Asturias; 2006.

Caballero Navarro A, Fernández Rodríguez I, Fernández Rodríguez M, García García L, García Haro J, García Velasco G et al. Guía de Recomendaciones Clínicas: Depresión. Asturias: Consejería de Sanidad y Servicios Sanitarios del Principado de Asturias; 2013.

Contreras A. Insomnio: Generalidades y Alternativas Terapéuticas de Última Generación.
Oyague López, L., & Mateos Campos, R. (2019). Outpatient Profile in Anxiolytic and/or Antidepressant Treatment. FarmaJournal, 4(2), 19–29. https://doi.org/10.14201/fj2019421929

Downloads

Download data is not yet available.
+